journal article·2021-12-15

Control Release Coating for Urinary Catheters with Enhanced Released Profile for Sustained Antimicrobial Protection

Esther Marie JieRong Lin, Chee Leng Lay, Gomathy Sandhya Subramanian, Wui Siew Tan, Susanna Su Jan Leong, Lionel Chuan Hui Moh, Kaiyang Lim

ACS Applied Materials & Interfaces· Volume 13· Issue 49
Publisher page

Abstract

Catheter-associated urinary tract infections (CAUTIs) are common and pose significant costs to healthcare systems. To date, this problem is largely unsolved as commercially available antimicrobial catheters are still lacking in functionality and performance. A prior study by Lim et al. ( Biotechnol. Bioeng. 2018, 115 (8), 2000-2012) reported the development of a novel anhydrous polycaprolactone (PCL) polymer formulation with controlled-release functionality for antimicrobial peptides. In this follow-up study, we developed an improved antimicrobial peptide (AMP)-impregnated poly(ethylene glycol) (PEG)-polycaprolactone (PCL) anhydrous polymer coating for enhanced sustained controlled-release functionality to provide catheters with effective antimicrobial properties. Varying the ratio of PEG and PEG-PCL copolymers resulted in polymers with different morphologies, consequently affecting the AMP release profiles. The optimal coating, formulated with 10% (w/w) PEG-PCL in PCL, achieved a controlled AMP release rate of 31.65 ± 6.85 μg/mL daily for up to 19 days, with a moderate initial burst release. Such profile is desired for antimicrobial coating as the initial burst release acts as a sterilizer to kill the bacteria present in the urinary tract upon insertion, and the subsequent linear release functions as a prophylaxis to deter opportunistic microbial infections. As a proof-of-concept application, our optimized coating was then applied to a commercial silicone catheter for further antibacterial tests. Preliminary results revealed that our coated catheters outperformed commercial silver-based antimicrobial catheters in terms of antimicrobial performance and sustainability, lasting for 4 days. Application of the controlled-release coating also aids in retarding biofilm formation, showing a lower extent of biofilm formation at the end of seven inoculation cycles.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Urinary Tract Infections Management · Urinary Bladder and Prostate Research · Surgical site infection prevention

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Institute of Materials Research and Engineering, Agency for Science, Technology and Research, 2 Fusionopolis Way, 138634 Singapore

Singapore Institute of Food and Biotechnology Innovation, Agency for Science, Technology and Research, 31 Biopolis Way, #01-02 Nanos, 138669 Singapore

Dornier Medtech Asia Pte Ltd., 2 Venture Drive, Vision Exchange, 608526 Singapore

Singapore Institute of Technology, 10 Dover Drive, 138683 Singapore

ES-TA Technology Pte Ltd., 21 Jalan Mesin, 368819 Singapore

Funding

Science and Engineering Research Council

References (51)

Show source-provided references
1. 10.1186/S13756-015-0097-910.1186/S13756-015-0097-9 ↗
2. Monegro A. F. · 2020 · 736
3. 10.1016/J.BIOMATERIALS.2016.11.04710.1016/J.BIOMATERIALS.2016.11.047 ↗
4. 10.1038/ncpuro123110.1038/ncpuro1231 ↗
5. 10.1039/B908260C10.1039/B908260C ↗
6. 10.7326/0003-4819-144-2-200601170-0000910.7326/0003-4819-144-2-200601170-00009 ↗
7. 10.1086/67571810.1086/675718 ↗
8. 10.1086/65048210.1086/650482 ↗
9. 10.1111/TID.1303110.1111/TID.13031 ↗
10. 10.1016/J.SPINEE.2017.05.02510.1016/J.SPINEE.2017.05.025 ↗
11. 10.1016/j.juro.2010.07.03610.1016/j.juro.2010.07.036 ↗
12. 10.1016/j.tibtech.2015.09.00210.1016/j.tibtech.2015.09.002 ↗
13. 10.3390/nano1008152710.3390/nano10081527 ↗
14. Lei J. · Am. J. Transl. Res. · 2019 · 11 · 3919
15. 10.3389/FMICB.2020.58277910.3389/FMICB.2020.582779 ↗
16. 10.1016/j.actbio.2014.12.01510.1016/j.actbio.2014.12.015 ↗
17. 10.1002/JBM.B.3270110.1002/JBM.B.32701 ↗
18. 10.1016/j.chembiol.2008.11.00610.1016/j.chembiol.2008.11.006 ↗
19. 10.1021/ma901356s10.1021/ma901356s ↗
20. 10.1016/j.biomaterials.2013.07.08910.1016/j.biomaterials.2013.07.089 ↗
21. Tiller J. C. · 2010 · 193
22. 10.1002/anie.20080357010.1002/anie.200803570 ↗
23. 10.1021/AM507371A10.1021/AM507371A ↗
24. 10.1021/ACS.IECR.6B0219010.1021/ACS.IECR.6B02190 ↗
25. 10.1021/ACSAMI.6B1118710.1021/ACSAMI.6B11187 ↗
26. 10.1016/j.jot.2018.09.00110.1016/j.jot.2018.09.001 ↗
27. 10.1542/peds.2017-323910.1542/peds.2017-3239 ↗
28. 10.1098/rsif.2010.059610.1098/rsif.2010.0596 ↗
29. 10.1002/bit.2671310.1002/bit.26713 ↗
30. 10.1016/j.actbio.2009.04.00710.1016/j.actbio.2009.04.007 ↗
31. 10.1016/j.progpolymsci.2010.04.00210.1016/j.progpolymsci.2010.04.002 ↗
32. 10.1016/J.JCONREL.2021.02.03110.1016/J.JCONREL.2021.02.031 ↗
33. 10.1016/j.actbio.2011.02.00210.1016/j.actbio.2011.02.002 ↗
34. 10.1016/j.jpba.2010.10.02710.1016/j.jpba.2010.10.027 ↗
35. 10.1016/j.ijpharm.2009.12.01010.1016/j.ijpharm.2009.12.010 ↗
36. 10.1016/j.jconrel.2010.05.01710.1016/j.jconrel.2010.05.017 ↗
37. 10.1016/j.biomaterials.2005.01.06310.1016/j.biomaterials.2005.01.063 ↗
38. 10.1016/j.ijpharm.2011.07.02010.1016/j.ijpharm.2011.07.020 ↗
39. 10.1002/jps.2416510.1002/jps.24165 ↗
40. 10.1080/00222348.2016.114693610.1080/00222348.2016.1146936 ↗
41. 10.1002/jps.2391010.1002/jps.23910 ↗
42. 10.1007/s10439-015-1389-110.1007/s10439-015-1389-1 ↗
43. 10.1021/acs.molpharmaceut.0c0051510.1021/acs.molpharmaceut.0c00515 ↗
44. 10.1002/APP.4896710.1002/APP.48967 ↗
45. 10.3390/POLYM1203071710.3390/POLYM12030717 ↗
46. 10.1002/jps.2382410.1002/jps.23824 ↗
47. 10.1186/s13018-018-0930-y10.1186/s13018-018-0930-y ↗
48. 10.3390/POLYM1212287610.3390/POLYM12122876 ↗
49. 10.1016/j.polymer.2017.04.00610.1016/j.polymer.2017.04.006 ↗
50. 10.1016/j.saa.2010.12.07910.1016/j.saa.2010.12.079 ↗
51. 10.4103/0300-1652.10354310.4103/0300-1652.103543 ↗